Form 4: Vanda Pharma GC Sells Shares for Tax Obligations

Vanda Pharmaceuticals' SVP & General Counsel, Timothy Williams, sold 42,434 shares of common stock to cover tax obligations from vested restricted stock units.

Summary

• Timothy Williams, SVP & General Counsel of Vanda Pharmaceuticals Inc. (VNDA), reported a sale of common stock.
• On March 2, 2026, Williams sold 42,434 shares of VNDA common stock.
• The shares were sold at a weighted average price of $8.2659, with individual transactions ranging from $8.085 to $8.81.
• The sale was executed to satisfy tax obligations related to the acquisition of shares from the settlement of vested Restricted Stock Units (RSUs).
• This transaction was conducted pursuant to the withholding tax provisions of the RSU agreements and was a pre-planned transaction under Rule 10b5-1(c).
• Following this transaction, Timothy Williams beneficially owns 377,450 shares of Vanda Pharmaceuticals common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. The sale is a routine, non-discretionary transaction for tax purposes related to RSU vesting, not indicative of a change in management's sentiment or company performance.

Positives

• The transaction is a non-discretionary sale for tax purposes, not indicative of a change in management's confidence in the company's future.
• The sale was executed under a Rule 10b5-1 plan, indicating it was pre-scheduled and not based on new material non-public information.

Negatives

• A reduction in insider ownership, even if for tax purposes, slightly decreases the alignment of management's personal financial interests with shareholders.

Future Outlook

No forward-looking statements or guidance are provided in this Form 4 filing, as it reports a past transaction.

Industry Context

StockSavvy.ai notes that routine insider sales for tax purposes, especially those executed under a Rule 10b5-1 plan, are common across the pharmaceutical industry and generally do not signal a change in company fundamentals or management's outlook. Such transactions are typically a function of executive compensation structures involving restricted stock units.

Comparison to Industry Standards

• StockSavvy.ai observes that sales of shares to cover tax obligations upon RSU vesting are standard practice for executives across various industries, including biotechnology and pharmaceuticals.
• This type of transaction is a common mechanism for managing executive compensation and tax liabilities, aligning with practices seen at companies like Pfizer, Merck, and Johnson & Johnson, where executives frequently sell a portion of vested equity to satisfy statutory withholding requirements.

Stakeholder Impact

• Shareholders: A minor reduction in insider ownership, but the non-discretionary nature of the sale mitigates concerns about management confidence.
• Employees: No direct impact on employees is indicated.
• Customers: No direct impact on customers is indicated.
• Suppliers: No direct impact on suppliers is indicated.
• Creditors: No direct impact on creditors is indicated.

Key Dates

Recommendation

This Form 4 filing reports a routine, non-discretionary sale of shares by an executive to cover tax obligations related to RSU vesting, executed under a Rule 10b5-1 plan. Such transactions are common and generally do not reflect a change in the executive's outlook on the company's prospects or fundamental performance. Therefore, it provides no new information that would warrant a change in investment recommendation; a 'hold' stance is maintained based solely on this filing.

Keywords

Vanda Pharmaceuticals, VNDA, Timothy Williams, Insider Trading, Form 4, Stock Sale, Restricted Stock Units, RSU, Tax Obligations, Corporate Governance, Executive Compensation